Taven20 mg

Taven 20 mg is prescribed alongside a cholesterol-lowering diet when diet and lifestyle changes alone are not enough to control lipid levels. It is indicated for the following conditions:

• Heterozygous and homozygous familial hypercholesterolemia — to lower total cholesterol and LDL cholesterol
• Mixed dyslipidemia (Fredrickson Type Ia and Ib) — to reduce elevated cholesterol and triglyceride levels
• Hypertriglyceridemia (Fredrickson Type IV) — to manage high serum triglyceride levels
• Dysbetalipoproteinemia (Fredrickson Type III) — as part of lipid management therapy
• Coronary artery disease — to reduce cardiac ischemic events in patients with asymptomatic or mild-to-moderate symptomatic CAD and elevated LDL cholesterol
• Hypercholesterolemia associated with diabetes mellitus or renal transplantation — to lower total and LDL cholesterol

Other Anti-anginal & Anti-ischaemic drugs, Statins

Taven 20 mg is a lipid-lowering agent belonging to the statin class. It works by selectively inhibiting HMG-CoA reductase, the key rate-limiting enzyme involved in the biosynthesis of cholesterol in the liver.

Mechanism of Action

Atorvastatin competitively inhibits HMG-CoA reductase, blocking the conversion of HMG-CoA to mevalonate, an essential precursor in cholesterol production. This leads to:

• Reduced hepatic cholesterol synthesis

• Increased expression of LDL receptors on liver cells

• Enhanced uptake and clearance of circulating low-density lipoprotein (LDL)

• Overall reduction in plasma levels of total cholesterol, LDL-C, Apo-B, and triglycerides

Additionally, atorvastatin contributes to improved lipid balance and may help stabilize atherosclerotic plaques, reducing cardiovascular risk.

Pharmacokinetics

Absorption

• Rapidly absorbed after oral administration

• Peak plasma concentrations achieved within 1–2 hours

• Absorption increases proportionally with dose

• Absolute bioavailability is approximately 14%, while systemic availability of HMG-CoA reductase inhibitory activity is about 30%

Distribution

• Mean volume of distribution: approximately 381 liters, indicating extensive tissue distribution

• Highly protein-bound (~98%)

• Low penetration into red blood cells (blood/plasma ratio ~0.25)

• Based on animal studies, atorvastatin may be excreted into human breast milk

Metabolism

• Extensively metabolized in the liver to active ortho- and para-hydroxylated metabolites

• These metabolites retain significant pharmacological activity

• Around 70% of HMG-CoA reductase inhibitory effect is due to active metabolites

• Primarily metabolized by cytochrome P450 3A4 (CYP3A4)

• Drug interactions may occur with CYP3A4 inhibitors (e.g., erythromycin), increasing atorvastatin plasma levels

Excretion

• Eliminated mainly via bile following hepatic and extra-hepatic metabolism

• Minimal renal excretion (<2% in urine)

• Does not undergo significant enterohepatic recirculation

Half-life

• Plasma elimination half-life: approximately 14 hours

• Duration of inhibitory activity: 20–30 hours, due to active metabolites

Summary

Taven 20 mg effectively reduces cholesterol synthesis and enhances LDL clearance through dual mechanisms—enzyme inhibition and receptor upregulation. Its pharmacokinetic profile supports once-daily dosing, with prolonged activity driven by active metabolites, making it a cornerstone therapy in managing dyslipidemia and preventing cardiovascular disease.

Atorvastatin can interact with several medications. Some interactions may increase the risk of serious side effects such as myopathy (muscle injury). Always inform your doctor about all medicines you are currently taking.

Interactions That Increase Myopathy Risk

• Cyclosporine: Concurrent use significantly raises the risk of muscle-related adverse effects
• Fibric acid derivatives (fibrates): Combination therapy increases myopathy risk; use with caution
• Niacin (nicotinic acid): Elevated risk of muscle damage when combined with atorvastatin
• Erythromycin: Inhibits CYP3A4 enzyme, increasing atorvastatin plasma concentrations by approximately 40%; myopathy risk rises
• Azole antifungals (e.g., fluconazole, itraconazole): May increase atorvastatin exposure via CYP3A4 inhibition

Other Notable Interactions

• Antacids: Co-administration reduces atorvastatin plasma levels by about 35%; however, LDL-C reduction remains unaffected
• Colestipol: Reduces atorvastatin plasma concentrations by approximately 25%, but LDL-C lowering is actually greater when both drugs are taken together than either alone
• Digoxin: Concurrent use raises steady-state digoxin plasma concentrations by roughly 20%; patients on digoxin should be monitored closely
• Oral contraceptives: Co-administration increases exposure to norethindrone by approximately 30% and ethinyl estradiol by approximately 20%; this should be factored in when choosing a contraceptive method
• Warfarin: Atorvastatin does not produce a clinically significant effect on prothrombin time in patients on chronic warfarin therapy; monitoring is still advisable

Taven 20 mg is generally well-tolerated. Most side effects are mild and resolve on their own. The following adverse effects have been reported:

Common Side Effects

• Constipation
• Flatulence (gas)
• Indigestion (dyspepsia)
• Abdominal pain or discomfort

Other Reported Side Effects

• Headache
• Muscle pain (myalgia) or joint pain (arthralgia)
• Back pain
• Skin rash
• General weakness (asthenia)
• Respiratory infections
• Fatigue
• Elevated blood sugar levels (particularly relevant in diabetic patients)

Serious Side Effects (Seek Immediate Medical Attention)

• Severe muscle weakness or unexplained muscle pain — may indicate myopathy or rhabdomyolysis
• Signs of liver problems: dark urine, yellowing of the skin or eyes (jaundice), or persistent upper abdominal pain
• Breathing difficulty
• Memory loss or confusion (rare)

Taven 20 mg is contraindicated during pregnancy and breastfeeding due to potential risks to the fetus and infant. Its use in women of childbearing potential requires careful consideration and appropriate precautions.

Pregnancy

• Contraindicated in pregnancy

• The safety of atorvastatin in pregnant women has not been established, as no controlled clinical trials have been conducted

Potential Risks

• Rare cases of congenital anomalies have been reported following intrauterine exposure to statins

• Animal studies have demonstrated reproductive toxicity

• Atorvastatin inhibits cholesterol synthesis, which may reduce fetal levels of mevalonate, a critical precursor for:

  • Cholesterol production

  • Cell membrane formation

  • Hormone synthesis

Clinical Recommendations

• Do not use in women who are:

  • Pregnant

  • Planning to become pregnant

  • Suspecting pregnancy

• If pregnancy occurs during treatment:

  • Discontinue atorvastatin immediately

  • Resume therapy only after pregnancy has been ruled out or completed

Lactation (Breastfeeding)

• Contraindicated during breastfeeding

Key Considerations

• It is unknown whether atorvastatin is excreted in human breast milk

• Animal studies indicate that atorvastatin and its metabolites are present in milk at levels similar to plasma

• There is a potential risk of serious adverse effects in nursing infants

Clinical Recommendations

• Women taking atorvastatin should not breastfeed

• Alternative feeding methods or lipid-lowering therapies should be considered

Summary

Taven 20 mg should not be used during pregnancy or lactation due to potential harm to the fetus and infant. Women of reproductive age should use effective contraception and discontinue therapy immediately if pregnancy is detected.

Liver Function

• Liver function tests should be carried out before starting atorvastatin and at regular intervals during therapy
• Use with caution in patients with a history of liver disease or those who consume significant amounts of alcohol
• Discontinue atorvastatin if liver enzyme levels rise markedly or if liver disease is suspected

Muscle-Related Risks

• Atorvastatin must be stopped immediately if myopathy (muscle disease) is diagnosed or suspected
• Significantly elevated creatine phosphokinase (CPK) levels are a signal to discontinue therapy
• Risk of myopathy increases when atorvastatin is combined with certain medications (see Drug Interactions)

Blood Sugar

• Atorvastatin may slightly raise blood glucose levels; diabetic patients should monitor blood sugar regularly during treatment

Cholesterol-Lowering Diet

• Patients should maintain a cholesterol-lowering diet before and throughout the entire course of atorvastatin therapy

Do Not Stop Without Medical Advice

• Stopping atorvastatin abruptly without consulting a doctor may worsen the underlying condition; always follow the prescribed course

There is no specific antidote for atorvastatin overdose. Management is supportive and symptomatic. The following measures apply:

• Provide symptomatic treatment and supportive care as clinically indicated
• Monitor liver function tests and serum creatine kinase (CK) levels closely
• Hemodialysis is not expected to be effective in removing atorvastatin from the body, as the drug is approximately 98% bound to plasma proteins
• Seek emergency medical attention immediately in the event of a suspected overdose

• Store at room temperature in a cool, dry place
• Keep away from direct sunlight, heat, and moisture
• Keep out of the reach of children and pets
• Do not use after the expiry date printed on the packaging

Pregnancy

• Atorvastatin is strictly contraindicated during pregnancy
• Safety in pregnant women has not been established through controlled clinical trials
• Rare cases of congenital anomalies have been reported following in-utero exposure to statins
• Animal studies have demonstrated reproductive toxicity; atorvastatin may reduce fetal cholesterol levels by limiting mevalonate production
• Women must not use atorvastatin if pregnant, planning to become pregnant, or if pregnancy is suspected; treatment should be suspended until pregnancy is ruled out

Lactation (Breastfeeding)

• It is unknown whether atorvastatin or its metabolites pass into human breast milk
• Animal studies show that drug concentrations in milk are comparable to plasma levels
• Due to the risk of serious adverse effects in nursing infants, atorvastatin is contraindicated during breastfeeding

Elderly Patients (≥65 Years)

• Plasma concentrations of atorvastatin are approximately 40% higher (Cmax) and 30% higher (AUC) in healthy elderly subjects compared to younger adults
• A greater LDL-lowering effect is observed at any given dose in older patients; dose selection should be made carefully

Pediatric Patients

• Atorvastatin may be used in children aged 10 years and above for familial hypercholesterolemia
• Pharmacokinetic data specific to the pediatric population are not currently available
• Maximum recommended dose in children aged 10–17 years is 20 mg/day

Renal Impairment

• Kidney disease does not significantly affect atorvastatin's plasma concentrations or LDL-lowering efficacy
• No dose adjustment is required in patients with renal impairment
• Hemodialysis is not expected to meaningfully enhance drug clearance due to high plasma protein binding (98%)

Hepatic Impairment

• In patients with chronic alcoholic liver disease, atorvastatin plasma concentrations are markedly elevated
• Use with caution and close monitoring in any patient with hepatic dysfunction

Gender

• There is no clinically significant difference in LDL-C reduction between male and female patients

Other Anti-anginal & Anti-ischaemic drugs, Statins

Atorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.

Pregnancy: Atorvastatin is contraindicated during pregnancy. Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction. Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atorvastatin should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with atorvastatin should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnantLactation: It is not known whether atorvastatin or its metabolites are excreted in human milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. Because of the potential for serious adverse reactions, women taking atorvastatin should not breastfeed their infants. Atorvastatin is contraindicated during breastfeeding.

Hepatic impairment: Taven 20 mg should be used with caution in patients with hepatic impairment. Pediatric use: For patients aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day with titration up to 20 mg per day. Taven 20 mg is not indicated in the treatment of patients below the age of 10 years.